Blood-Brain Barrier Disruption Chemotherapy

John M. McGregor, Susan D. Bell, Nancy Doolittle, Tulio P. Murillo, Edward Neuwelt

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Scopus citations

Abstract

The goal of chemotherapy administered in conjunction with blood-brain barrier disruption (BBBD) is maximizing drug delivery to the brain, while preserving the neurocognitive function and minimizing systemic toxicity. In the clinic, BBBD has shown promising results in chemosensitive brain tumors such as the primary central nervous system lymphoma (PCNSL) and offers a new strategy for global delivery of chemotherapy to tumors such as anaplastic oligodendroglioma and central nervous system metastases. Multicenter clinical trials using BBBD are in progress at centers participating in the blood-brain barrier (BBB) Consortium. Current and future clinical studies include delivery of mAbs across the BBB and novel imaging agents to monitor therapeutics.

Original languageEnglish (US)
Title of host publicationHandbook of Brain Tumor Chemotherapy, Molecular Therapeutics, and Immunotherapy
Subtitle of host publicationSecond Edition
PublisherElsevier Inc.
Pages145-153
Number of pages9
ISBN (Print)9780128121009
DOIs
StatePublished - Apr 24 2018

    Fingerprint

Keywords

  • Blood-brain barrier disruption
  • Brain tumors
  • Chemotherapy
  • Primary CNS lymphoma

ASJC Scopus subject areas

  • Medicine(all)
  • Neuroscience(all)

Cite this

McGregor, J. M., Bell, S. D., Doolittle, N., Murillo, T. P., & Neuwelt, E. (2018). Blood-Brain Barrier Disruption Chemotherapy. In Handbook of Brain Tumor Chemotherapy, Molecular Therapeutics, and Immunotherapy: Second Edition (pp. 145-153). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-812100-9.00010-3